Medical Education Library

Calcipotriene-Betamethasone Dipropionate Foam in the Management of Psoriasis: A Panoramic View of Available Studies with Emphasis on Clinical Relevance

A supplement to Dermatology News™. This supplement was sponsored by LEO Pharma Inc.

 

In this supplement you will learn about:

  • The formulation characteristics of calcipotriene-betamethasone dipropionate aerosol foam (Cal/BD-AF)
  • The efficacy and safety of Cal/BD-AF
  • The results of Phase III clinical trials completed with Cal/BD-AF

Author
James Q. Del Rosso, DO, FAOCD, FAAD
Adjunct Clinical Professor (Dermatology), Touro University Nevada, Henderson, Nevada

Lakes Dermatology and Del Rosso Dermatology Research Center, Las Vegas, Nevada

 

Dr. Del Rosso discloses that he is a consultant, speaker, and researcher for LEO Pharma Inc. Related to this subject area he is also a consultant, speaker, and/or researcher for Aqua Pharmaceuticals/Almirall, S.A.; Bayer AG; Celgene Corporation; Galderma Laboratories, L.P.; Genentech, Inc.; Novan, Inc.; Novartis Pharmaceuticals Corporation; Pfizer Inc. /Anacor Pharmaceuticals, Inc.; PharmaDerm; Promius Pharma, LLC; Sun Pharmaceutical Industries, Ltd.; and Valeant Pharmaceuticals International, Inc.


Click here to download this supplement. 

Recommended for You

News & Commentary

Quizzes from MD-IQ

Research Summaries from ClinicalEdge

Next Article: